Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Phase 3

Completed

• Conditions: Staphylococcus Aureus Infection
• Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Flucloxacillin; Drug: Clindamycin; Drug: Cloxacillin; Drug: Linezolid; Drug: Vancomycin; Drug: Daptomycin; Drug: Cefazolin

• Registration Number: NCT01792804
• Lead Sponsor: Heinrich-Heine University, Duesseldorf

Brief Summary

Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade \[1\]. This threat underscores the need to maximize clinical utility of existing antibiotics, through more rational prescription, e.g. optimizing duration of treatment.

Staphylococcus aureus bloodstream infection (SAB) is a common disease with about 200,000 cases occurring annually in Europe \[2\]. A course of at least 14 days of intravenous antimicrobials is considered standard therapy \[3-5\] in "uncomplicated" SAB. This relatively long course serves to prevent SAB-related complications (such as endocarditis and vertebral osteomyelitis) that may result from hematogenous dissemination to distant sites. However, there is insufficient evidence that a full course of intravenous antibiotic therapy is always required in patients with a low risk of SAB-related complications.

In a multicenter, open-label, randomized controlled trial we aim to demonstrate that an early switch from intravenous to oral antimicrobial therapy is non-inferior to a conventional 14-days course of intravenous therapy regarding efficacy and safety. An early switch from intravenous to oral therapy would provide several benefits such as earlier discharge, fewer adverse reactions associated with intravenous therapy, increased quality of life, and cost savings.

Detailed Description

1. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health Organization, 2001.

2. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010;23(4):346-58.

3. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57(4):589-608.

4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55.

5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.

Study Timeline

• Study First Submitted: 2013-02-13
• Study First Submitted QC: 2013-02-14
• Study First Posted: 2013-02-15
• Study Start: 2013-12
• Primary Completion: 2020-03-26
• Study Completion: 2020-03-26
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-26
• Last Update Posted: 2020-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 215

Inclusion Criteria

• Age at least 18 years

• Not legally incapacitated

• Written informed consent from the trial subject has been obtained

• Blood culture positive for S. aureus not considered to represent contamination

• At least one negative follow-up blood culture obtained within 24-96 hours after the start of adequate antimicrobial therapy to rule out persistent bacteremia and Absence of a blood culture positive for S. aureus at the same time or thereafter.

• Five to seven full days of appropriate i.v. antimicrobial therapy administered prior to randomization documented in the patient Chart. Appropriate therapy has all of the following characteristics:

  1. Antimicrobial therapy has to be initiated within 72h after the first positive blood culture was drawn.

  2. Provided in-vitro susceptibility and adequate dosing (as judged by the PI) preferred agents for pre-randomization antimicrobial therapy are flucloxacillin, cloxacillin, vancomycin and daptomycin. However, the following antimicrobials are allowed:

     • MSSR: penicillinase-resistant penicillins (e.g. flucloxacillin, cloxacillin), β-lactam plus β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except ceftazidime), carbapenems, clindamycin, fluoroquinolones, trimethoprimsulfamethoxazole, doxycycline, tigecycline, vancomycin, teicoplanin, telavancin, linezolid, daptomycin, ceftaroline, ceftobiprole, and macrolides.
     • MRSA: vancomycin, teicoplanin, telavancin, fluoroquinolones, clindamycin, trimethoprim-sulfamethoxazole, doxycycline, tigecycline, linezolid, daptomycin, macrolides, ceftaroline, and ceftobiprole.

Exclusion Criteria

• Polymicrobial bloodstream infection, defined as isolation of pathogens other than S. aureus from a blood culture obtained in the time from two days prior to the first positive blood culture with S. aureus until randomization. Common skin contaminants (coagulase-negative staphylococci, diphtheroids, Bacillus spp., and Propionibacterium spp.) detected in one of several blood cultures will not be considered to represent polymicrobial infection

• Recent history (within 3 months) of prior S. aureus bloodstream infection

• In vitro resistance of S. aureus to all oral or all i.v. study drugs

• Contraindications for all oral or all i.v. study drugs

• Previously planned Treatment with active drug against S. aureus during Intervention Phase (e.g. cotrimoxazol prophylaxis)

• Signs and symptoms of complicated SAB as judged by an ID physician. Complicated infection is defined as at least one of the following:

  • deep-seated focus: e.g. endocarditis, pneumonia, undrained abscess, empyema, and Osteomyelitis
  • septic shock, as defined by the AACP criteria (23), within 4 days before randomization
  • prolonged bacteremia: positive follow-up blood culture more than 72h after the start of adequate antimicrobial therapy
  • body temperature >38 °C on two separate days within 48h before randomization

• Presence of the following non-removable foreign bodies (if not removed 2 days or more before randomization):

  • prosthetic heart valve
  • deep-seated vascular graft with foreign material (e.g. PTFE or dacron graft). Hemodialysis shunts are not considered deep-seated vascular grafts.
  • ventriculo-atrial shunt

• Presence of a prosthetic joint (if not removed 2 days or more before randomization). This is not an exclusion criterion, if all of the following conditions are fulfilled:

  • prosthetic joint was implanted at least 6 months prior, and
  • catheter-related infection, skin and soft tissue infection, or surgical wound infection is present (as defined below), and
  • joint infection unlikely (no clinical or imaging signs)

• Presence of a pacemaker or an automated implantable cardioverter Defibrillator (AICD) device (if not removed 2 days or more before randomization). This is not an exclusion criterion, if all of the following conditions are fulfilled:

  • pacemaker or AICD was implanted at least 6 months prior, and
  • catheter-related infection, skin and soft tissue infection, or surgical wound infection is present (as defined below), and
  • no clinical signs of infective endocarditis, and
  • infective endocarditis unlikely by echocardiography (preferably TEE), and
  • pocket infection unlikely (no clinical or imaging signs)

• Failure to remove any intravascular catheter which was present when first positive blood culture was drawn within 4 days of the first positive blood culture

• Severe liver disease. This is not an exclusion criterion, if the following condition is fulfilled:

  • catheter-related infection, skin and soft tissue infection, or surgical wound infection is present

• End-stage renal disease. This is not an exclusion criterion, if all of the following conditions are fulfilled:

  • catheter-related infection, skin and soft tissue infection, or surgical wound infection is present (as defined below), and
  • no clinical signs of infective endocarditis, and
  • infective endocarditis unlikely by echocardiography (preferably TEE), and
  • in patients with a hemodialysis shunt with a non-removable foreign body (e.g. synthetic PTFE loop): no clinical signs of a shunt infection

• Severe immunodeficiency

  • primary immunodeficiency disorders
  • neutropenia (<500 neutrophils/μl) at randomization or neutropenia expected during intervention phase due to immunosuppressive treatment
  • uncontrolled disease in HIV-positive patients
  • high-dose steroid therapy (>1 mg/kg prednisone or equivalent doses given for >4 weeks or planned during intervention)
  • immunosuppressive combination therapy with two or more drugs with different mode of action
  • hematopoietic stem cell transplantation within the past 6 months or planned during treatment period
  • solid organ transplant
  • treatment with biologicals within the previous year

• Life expectancy < 3 months

• Inability to take oral drugs

• Injection drug user

• Expected low compliance with drug regimen

• Participation in other interventional trials within the previous three months or ongoing

• Pregnant women and nursing mothers

• For premenopausal women: Failure to use highly-effective contraceptive methods for 1 month after receiving study drug. The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly-effective:

  • oral hormonal contraception ('pill')
  • dermal hormonal contraception
  • vaginal hormonal contraception (NuvaRing®)
  • contraceptive plaster
  • long-acting injectable contraceptives
  • implants that release progesterone (Implanon®)
  • tubal ligation (female sterilisation)
  • intrauterine devices that release hormones (hormone spiral)
  • double barrier methods

• Persons with any kind of dependency on the investigator or employed by the sponsor or investigator

• Persons held in an institution by legal or official order

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Orally administered antibiotic	Trimethoprim-Sulfamethoxazole	First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
Orally administered antibiotic	Linezolid	First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
Orally administered antibiotic	Clindamycin	First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
Intravenously administered antibiotic	Flucloxacillin	First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
Intravenously administered antibiotic	Cloxacillin	First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
Intravenously administered antibiotic	Vancomycin	First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
Intravenously administered antibiotic	Daptomycin	First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
Intravenously administered antibiotic	Cefazolin	First choice (MSSA): flucloxacillin \[Spain: cloxacillin\], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days

Primary Outcome Measures

Name	Time	Method
SAB-related complications	90 days	S. aureus bloodstream infection-related complications (relapsing SAB, deep-seated infection with S. aureus, or attributable mortality) within 90 days

Secondary Outcome Measures

Name	Time	Method
Length of hospital stay	90 days	Length of hospital stay
Survival	14, 30, and 90 days	Survival at 14, 30, and 90 days
Complications of intravenous therapy	90 days	Complications of intravenous therapy, such as thrombophlebitis.

Trial Locations

Locations (40)

Amsterdam; 🇳🇱 Amsterdam, Netherlands

Tilburg; 🇳🇱 Tilburg, Netherlands

Diakonessenhuis Utrecht; 🇳🇱 Utrecht, Netherlands

Paris 1; 🇫🇷 Paris, France

Paris 2; 🇫🇷 Paris, France

Breda; 🇳🇱 Breda, Netherlands

Nottingham; 🇬🇧 Nottingham, United Kingdom

Uniklinik Köln; 🇩🇪 Cologne, Germany

Nantes; 🇫🇷 Nantes, France

Rennes; 🇫🇷 Rennes, France

St. Etienne; 🇫🇷 Saint Etienne, France

Leverkusen; 🇩🇪 Leverkusen, Germany

Orléans; 🇫🇷 Orléans, France

Freiburg; 🇩🇪 Freiburg, Germany

Groningen; 🇳🇱 Groningen, Netherlands

Jena; 🇩🇪 Jena, Germany

Barcelona II; 🇪🇸 Barcelona, Spain

Sevilla; 🇪🇸 Sevilla, Spain

Paris 5; 🇫🇷 Paris, France

UMC Groningen; 🇳🇱 Groningen, Netherlands

La Roche-sur-Yon; 🇫🇷 La Roche-sur-Yon, France

Berlin; 🇩🇪 Berlin, Germany

Lübeck; 🇩🇪 Lübeck, Germany

Barcelona I; 🇪🇸 Barcelona, Spain

Paris 3; 🇫🇷 Paris, France

Ulm; 🇩🇪 Ulm, Germany

Düsseldorf; 🇩🇪 Dusseldorf, Germany

Paris 4; 🇫🇷 Paris, France

Chambéry; 🇫🇷 Chambéry, France

Quimper; 🇫🇷 Quimper, France

Frankfurt; 🇩🇪 Frankfurt/Main, Germany

Palma; 🇪🇸 Palma de Mallorca, Spain

Krefeld; 🇩🇪 Krefeld, Germany

Sevilla II; 🇪🇸 Sevilla, Spain

VUmc Amsterdam; 🇳🇱 Amsterdam, Netherlands

Hannover; 🇩🇪 Hannover, Germany

Utrecht; 🇳🇱 Utrecht, Netherlands

Tours; 🇫🇷 Tours, France

Annecy; 🇫🇷 Annecy, France

Grenoble; 🇫🇷 Grenoble, France